IP Verse

Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna - EP2611461

The patent EP2611461 was granted to Glaxosmithkline on Mar 9, 2022. The application was originally filed on Aug 31, 2011 under application number EP11758014A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2611461

GLAXOSMITHKLINE
Application Number
EP11758014A
Filing Date
Aug 31, 2011
Status
Granted And Under Opposition
Feb 4, 2022
Grant Date
Mar 9, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONDec 9, 2022MEWBURN ELLISADMISSIBLE
THOMANNDec 9, 2022-ADMISSIBLE
WEICKMANN & WEICKMANNDec 9, 2022-ADMISSIBLE
SANOFIDec 6, 2022ELKINGTON AND FIFEADMISSIBLE

Patent Citations (59) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20110378826-
DESCRIPTIONWO0202606
DESCRIPTIONWO0234771
DESCRIPTIONWO03018054
DESCRIPTIONWO2005002619
DESCRIPTIONWO2005032582
DESCRIPTIONWO2005111066
DESCRIPTIONWO2005113782
DESCRIPTIONWO2005121348
DESCRIPTIONWO2006089264
DESCRIPTIONWO2006091517
DESCRIPTIONWO2006110413
DESCRIPTIONWO2006138004
DESCRIPTIONWO2007049155
DESCRIPTIONWO2008020330
DESCRIPTIONWO2009016515
DESCRIPTIONWO2009031043
DESCRIPTIONWO2009086558
DESCRIPTIONWO2009104092
DESCRIPTIONWO2009109860
DESCRIPTIONWO2010119343
DESCRIPTIONWO2011005799
EXAMINATIONWO2011005799
INTERNATIONAL-SEARCH-REPORTWO2008103276
INTERNATIONAL-SEARCH-REPORTWO2009086558
INTERNATIONAL-SEARCH-REPORTWO2009111088
OPPOSITIONWO0003683
OPPOSITIONWO02095023
OPPOSITIONWO2005120152
OPPOSITIONWO2005121348
OPPOSITIONWO2007047749
OPPOSITIONWO2011005799
OPPOSITIONWO2011008974
OPPOSITIONWO2011068810
OPPOSITIONWO2012006369
OPPOSITIONWO2012006372
OPPOSITIONWO2012006376
OPPOSITIONWO2012006377
OPPOSITIONWO2012006378
OPPOSITIONWO2012030901
OPPOSITIONWO2012031043
OPPOSITIONWO2014160243
OPPOSITIONWO2017049245
OPPOSITIONWO2017075531
OPPOSITIONWO2022137133
OPPOSITIONWO9011092
OTHEREP0910576
OTHERUS5820873
OTHERUS6858224
OTHERWO2005026372
OTHERWO2005089148
OTHERWO2005120152
OTHERWO2009086558
OTHERWO2011005799
OTHERWO2012006369
OTHERWO2012006372
OTHERWO2012006376
OTHERWO2012006378
OTHERWO9952503

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "m7G(5')ppp(5')G RNA Cap Structure Analog", The New England Biolabs, (20100401), pages 1 - 2, XP093024994-
OPPOSITION- Anonymous, "ScriptCapâ„¢ m7G Capping System", The Epicentre Biotechnologies, (20061101), pages 1 - 2, XP093024996-
OPPOSITION- BANGS J. D., ET AL., "MASS SPECTROMETRY OF MRNA CAP 4 FROM TRYPANOSOMATIDS REVEALS TWO NOVEL NUCLEOSIDES.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19920515), vol. 267., no. 14., ISSN 0021-9258, pages 9805 - 9815., XP000608118-
OPPOSITION- "Chapter 9: Liposomal Formulations for Nucleic Acid Delivery", Stanley T. Crooke, Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition, (20070725), vol. 11, pages 237 - 270, XP055534618-
OPPOSITION- IMMORDINO et al., "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", Intl. J. Nanomed., (20060000), vol. 1, pages 297 - 315, XP009145524-
OPPOSITION- Immordino Maria Laura; Dosio Franco; Cattel Luigi, "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD., AUCKLAND, NZ, AUCKLAND, NZ , (20060101), vol. 1, no. 3, ISSN 1176-9114, pages 297 - 315, XP009145524-
OPPOSITION- MacLachlan I., "Liposomal formulations for nucleic acid delivery", MacLachlan I., CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY:PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED., US , CRC PRESS , (20070101), pages 237 - 270, ISBN 978-0-8493-8796-8, XP002584305-
OPPOSITION- PASCOLO STEVE, "Messenger RNA-based vaccines.", Expert opinion on biological therapy, Informa Healthcare, UK, UK , (20040801), vol. 4, no. 8, ISSN 1744-7682, pages 1285 - 1294, XP002764729-
OPPOSITION- ProductlnfoNow. Modern Drug Discovery, vol. 6, no. 6, (20030600), pages 57 - 62, URL: http://pubsapp.acs.org/subscribe/archive/mdd/v06/i06/toc/toc_i06. htm l-
OPPOSITION- VAN DEN BERG et al., "Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity", J Control Release, (20100125), vol. 141, no. 2, pages 234 - 40, XP026815097-
OPPOSITION- van den Berg, J.H. ; Oosterhuis, K. ; Hennink, W.E. ; Storm, G. ; van der Aa, L.J. ; Engbersen, J.F.J. ; Haanen, J.B.A.G. ; Beijnen, J.H. ; Schumacher, T.N. ; Nuijen, B., "Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity", Journal of Controlled Release, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20100125), vol. 141, no. 2, ISSN 0168-3659, pages 234 - 240, XP026815097-
OPPOSITION- Shayne Cox, Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043
OPPOSITION- MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome- entrapped mRNA", Eur. J. Immunol., (19930000), vol. 23, doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540
OPPOSITION- MARTINON F., ET AL., "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930101), vol. 23., doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722., XP000618955
OPPOSITION- LI et al., "Low-pH-sensitive polyethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery", Journal of Gene Medicine, (20050000), vol. 7, doi:10.1002/JGM.634, pages 67 - 79, XP008126013
OPPOSITION- PASCOLO S., "Vaccination with messenger RNA (mRNA", Handb Exp Pharmacol, (20080000), doi:10.1007/978-3-540-72167-3_11, pages 221 - 35, XP001538300
OPPOSITION- HESS et al., "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", Cancer Immunol Immunother, (20060600), vol. 55, no. 6, doi:10.1007/s00262-005-0064-z, pages 672 - 83, XP019333249
OPPOSITION- JEFFS et al., "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (20050000), vol. 22, doi:10.1007/s11095-004-1873-z, pages 362 - 372, XP019370801
OPPOSITION- KLIBANOV A L, ET AL., "AMPHIPATHIC POLYETHYLENEGLYCOLS EFFECTIVELY PROLONG THE CIRCULATION TIME OF LIPOSOMES", FEBS Letters, ELSEVIER, AMSTERDAM., NL, NL , (19900701), vol. 268, no. 01, doi:10.1016/0014-5793(90)81016-H, ISSN 0014-5793, pages 235 - 237, XP001073450
OPPOSITION- WILSON et al., "The Introduction of Poliovirus RNA into Cells via Lipid Vesicles (Liposomes", Cell, (19790000), vol. 17, doi:10.1016/0092-8674(79)90296-4, pages 77 - 84, XP023910555
OPPOSITION- ZHOU X., ET AL., "SELF-REPLICATING SEMLIKI FOREST VIRUS RNA AS RECOMBINANT VACCINE.", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19940101), vol. 12., no. 16., doi:10.1016/0264-410X(94)90074-4, ISSN 0264-410X, pages 1510 - 1514., XP002021790
OPPOSITION- AMBEGIA et al., "Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression", Biochimica et Biophysica Acta, (20050000), vol. 1669, no. 2, doi:10.1016/j.bbamem.2005.02.001, pages 155 - 63, XP004890715
OPPOSITION- Santos, A.O. ; da Silva, L.C.G. ; Bimbo, L.M. ; de Lima, M.C.P. ; Simoes, S. ; Moreira, J.N., "Design of peptide-targeted liposomes containing nucleic acids", Biochimica et Biophysica Acta, AMSTERDAM, NL , (20100301), vol. 1798, no. 3, doi:10.1016/j.bbamem.2009.12.001, ISSN 0005-2736, pages 433 - 441, XP026916011
OPPOSITION- HATAKEYAMA et al., "Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid", Biomaterials, (20110322), vol. 32, doi:10.1016/j.biomaterials.2011.02.045, pages 4306 - 4316, XP028245765
OPPOSITION- YAMAMOTO et al., "Current prospects for mRNA gene delivery", Eur J Pharm Biopharm, (20090300), vol. 71, no. 3, doi:10.1016/j.ejpb.2008.09.016, pages 484 - 9, XP025992169
OPPOSITION- KIM et al., "Enhanced siRNA delivery using cationic liposomes with new polyarginine- conjugated PEG-lipid", International Journal of Pharmaceutics, (20100000), vol. 392, pages 141 - 147, XP027044515
OPPOSITION- Schoenmaker Linde et al, "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20210501), vol. 601, doi:10.1016/j.ijpharm.2021.120586, ISSN 0378-5173, page 120586, XP055828800
OPPOSITION- HEYES et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Controlled Release, (20050000), vol. 107, doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522
OPPOSITION- James Heyes et al, "'Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", Journal of Controlled Release, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20050101), vol. 107, no. 2, doi:10.1016/j.jconrel.2005.06.014, ISSN 0168-3659, pages 276 - 287, XP008157522
OPPOSITION- OBATA et al., "Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo", J. Controlled Release, (20091025), vol. 142, doi:10.1016/j.jconrel.2009.10.023, pages 267 - 276, XP026905290
OPPOSITION- Hassett Kimberly J. et al, "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines", Molecular Therapy-Nucleic Acids, Cell Press, US, US , (20190415), vol. 15, doi:10.1016/j.omtn.2019.01.013, ISSN 2162-2531, pages 1 - 11, XP055815007
OPPOSITION- LAMBERT et al., "Intradermal vaccine delivery: will new delivery systems transform vaccine administration?", Vaccine, (20080619), vol. 26, no. 26, doi:10.1016/j.vaccine.2008.03.095, pages 3197 - 208, XP022710568
OPPOSITION- FURUICHI et al., "Viral and cellular mRNA capping: past and prospects", Adv Virus Res, (20000000), vol. 55, doi:10.1016/S0065-3527(00)55003-9, pages 135 - 84, XP009124440
OPPOSITION- KARIKO et al., "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", Molecular Therapy, (20080000), vol. 16, doi:10.1038/mt.2008.200, pages 1833 - 1840, XP055920956
OPPOSITION- KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556
OPPOSITION- ZIMMERMANN TRACY S ET AL, "RNAi-mediated gene silencing in non-human primates.", Nature, Nature Publishing Group UK, London, London, (20060504), vol. 441, no. 7089, doi:10.1038/nature04688, ISSN 0028-0836, pages 111 - 114, XP002412249
OPPOSITION- Akinc Akin et al, "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs", Nature Nanotechnology, Nature Pub. Group, Inc., London, London , (20191201), vol. 14, no. 12, doi:10.1038/s41565-019-0591-y, ISSN 1748-3387, pages 1084 - 1087, XP036953174
OPPOSITION- Norbert Pardi, Et Al., "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20180604), vol. 215, no. 6, doi:10.1084/jem.20171450, ISSN 0022-1007, pages 1571 - 1588, XP055545604
OPPOSITION- W-Z Zhou et al, "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (19991101), vol. 10, no. 16, ISSN 1043-0342, pages 2719 - 2724, XP002660042
OPPOSITION- FECHTER P, BROWNLEE G G, "Recognition of mRNA cap structures by viral and cellular proteins", Journal of General Virology, Society for General Microbiology, (20050101), vol. 86, doi:10.1099/VIR.0.80755-0, ISSN 0022-1317, pages 1239 - 1249, XP002516933
OPPOSITION- Banerjee Amiya K, "5'-Terminal Cap Structure in Eucaryotic Messenger Ribonucleic Acids", Microbiological Reviews, (19800601), vol. 44, no. 2, pages 175 - 205, XP055897139
OPPOSITION- Kawano, Et Al., "Effects of Polyethylene Glycol Spacer Length and Ligand Density on Folate Receptor Targeting of Liposomal Doxorubicin In Vitro", J. Drug. Delivery, (20110101), doi:10.1155/2011/160967, pages 1 - 6, XP055626067
OPPOSITION- SONOKE et al., "Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes", Cancer Research, (20080000), vol. 68, doi:10.1158/0008-5472.CAN-08-0127, pages 8843 - 8851, XP055046252
OPPOSITION- PASCOLO, "Vaccination with Messenger RNA", Methods in Molecular Medicine, (20060000), vol. 127, pages 23 - 40, XP009117840
OPPOSITION- Sticchi L, Alberti M, Alicino C, Crovari P, "The intradermal vaccination: past experiences and current perspectives", Journal of Preventive Medicine and Hygiene, IT, IT , (20100301), vol. 51, no. 1, doi:10.15167/2421-4248/jpmh2010.51.1.196, ISSN 1121-2233, pages 7 - 14, XP093010888
OPPOSITION- PASCOLO S., "Messenger RNA-based vaccines", Expert Opin Biol Ther, (20040800), vol. 4, no. 8, doi:10.1517/14712598.4.8.1285, pages 1285 - 94, XP009095328
OPPOSITION- Morais Pedro et al, "The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines", Frontiers in Cell and Developmental Biology, vol. 9, doi:10.3389/fcell.2021.789427, XP055885272

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents